Clinical trial
An Intermediate-Size, Expanded Access to SUVN-502 for the Treatment of Subjects With Alzheimer's Disease Who Have Completed the CTP2S1502HT6 Study
NCT03564964 is registered in ClinicalTrials.gov with Suven Life Sciences Limited as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Intermediate-Size, Expanded Access to SUVN-502 for the Treatment of Subjects With Alzheimer's Disease Who Have Completed the CTP2S1502HT6 Study
- Lead sponsor
- Suven Life Sciences Limited
- Phase
- Expanded access
- Overall status
- No longer available
- Start date
- Not reported
- Completion date
- Not reported
- Enrollment
- Not reported
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.